The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel, MD, Medical University of Vienna, Vienna, Austria, discusses production failure and out-of-specification production during the manufacturing of novel CAR-T cellular therapies. Investigational surveys were issued to 202 EBMT centers, revealing fewer manufacturing failures in CD19-targeted CAR-Ts compared to BCMA-targeted CAR-Ts. Given the differences in CAR-T commercialization and approval globally, the extent of patient pre-treatment, and the nature of patient pathologies, out-of-specification usage varies between lymphoma and myeloma. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research grants: Sanofi Genzyme, Therakos Malinckrodt
Advisory Boards: BMS Celgene, Kite Gilead, Novartis, Sanofi Genzyme
Speaker’s fees: Kite Gilead, Novartis, Pierre Fabre, Sanofi Genzyme, Therakos Malinckrodt
Travel Support: BMS Celgene, Kite Gilead, Novartis, Pierre Fabre, Sanofi Genzyme
